Billiontoone (NASDAQ:BLLN) Shares Down 5.8% – Time to Sell?

Billiontoone, Inc. (NASDAQ:BLLN) shares traded down 5.8% on Tuesday . The stock traded as low as $90.16 and last traded at $90.67. 130,921 shares changed hands during mid-day trading, a decline of 36% from the average session volume of 204,104 shares. The stock had previously closed at $96.29.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BLLN. Piper Sandler restated an “overweight” rating on shares of Billiontoone in a report on Wednesday, December 10th. BTIG Research reissued a “buy” rating and set a $160.00 price target on shares of Billiontoone in a research report on Wednesday, December 10th. Wall Street Zen upgraded shares of Billiontoone to a “hold” rating in a research note on Saturday, November 15th. JPMorgan Chase & Co. cut their price target on shares of Billiontoone from $150.00 to $145.00 and set an “overweight” rating on the stock in a report on Wednesday, December 10th. Finally, Jefferies Financial Group began coverage on Billiontoone in a research report on Monday, December 1st. They issued a “hold” rating and a $117.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $137.83.

Billiontoone Trading Down 6.4%

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings data on Tuesday, December 9th. The company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.06). The business had revenue of $83.52 million for the quarter, compared to analyst estimates of $82.86 million.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.